Robert Cozart Promoted to VP of Technical Operations at Zynex

LITTLETON, Colo.--(BUSINESS WIRE)-- Zynex, Inc. (OTCBB: ZYXI), a provider of pain management systems and electrotherapy products for medical patients with functional disability, announces the promotion of Robert Cozart to VP of Technical Operations at Zynex Medical.

Robert has worked for Zynex for over three years as operations manager and has been responsible for all production activities. In his new position, Robert will be responsible for production, warehousing, shipping and receiving, research and development and purchasing.

Thomas Sandgaard, CEO, stated: "I am excited to announce Robert’s promotion, as it continues to align the organization with our aggressive growth strategy. Robert has done a spectacular job in production, especially keeping up with the significant increase in revenue we have achieved over the last three years. We believe that Robert is up for the challenge to support our product development efforts and continued revenue growth.”

Robert has over 26 years of management experience in electronics manufacturing, primarily with Class II and Class III medical devices with such companies as HEI, Colorado Medtech, Pfizer/Valleylab and Medtronic. Robert holds an MBA from Creighton University in Omaha and a BS in Business from the University of Colorado in Boulder.

About Zynex

Zynex, Inc. (founded in 1996) engineers, manufactures, markets and sells its own design of electrotherapy medical devices in two distinct markets: standard digital electrotherapy products for pain relief and pain management; and the NeuroMove(TM) for stroke and spinal cord injury rehabilitation. Zynex's product lines are fully developed, FDA-cleared, commercially sold, and have been developed to uphold the Company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain. Zynex has also announced the development of two new business units, Zynex Monitoring Solutions and Zynex NeuroDiagnostic.

Safe Harbor Statement

Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital in order to grow our business, our ability to engage additional sales representatives, the success of such additional sales representatives, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the uncertain outcome of pending material litigation and other risks described in our filings with the Securities and Exchange Commission including the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2009.